肝复方对原发性肝癌模型小鼠肠道菌群影响的实验研究

Influence of compound liver prescription on intestinal microbiota in mice with primary hepatic carcinoma

目的:探讨肝复方对原发性肝癌(PHC)模型小鼠肠道菌群的影响,为肝复方治疗PHC的作用机制提供实验依据。方法:于92只ICR小鼠中取32只,随机分为正常1组与模型1组,每组16只,观察PHC小鼠造模前后肠道菌群的变化。另60只随机分为正常2组、模型2组、益生菌组、肝复方组,每组15只。肝复方组给予肝复方灌胃,剂量为15.6mg/(kg·d),模型2组、正常2组分别给予等量无菌水灌胃,益生菌组给予益生菌VSL#3灌胃,剂量为6mg/(kg·d)。每天灌胃1次,灌胃剂量均为临床等效剂量,连续用药14d。观察肝复方对PHC小鼠肠道菌群的影响。结果:PHC小鼠造模后双歧杆菌、乳酸杆菌、大肠埃希菌、肠球菌数量均多于造模前,差异有统计学意义(P<0.05)。与模型2组比较,肝复方组、益生菌组所研究肠道菌群数量均下降,差异有统计学意义(P<0.05);肝复方组的肠道细菌及益生菌组的乳酸杆菌、大肠埃希菌、肠球菌与正常2组比较,差异无统计学意义(P>0.05);肝复方组的乳酸杆菌、大肠埃希菌、肠球菌与益生菌组比较,差异无统计学意义(P>0.05)。结论:PHC模型小鼠存在肠道菌群失衡情况,肝复方能有效调节紊乱的PHC模型小鼠的肠道菌群。

Objective： To investigate the influence of compound liver prescription on intestinal microbiota in mice with primary hepatic carcinoma（ PHC）,and to provide an experimental basis for the mechanism of action of compound liver prescription in the treatment of PHC. Methods： A total of 92 ICR mice were selected; 32 of them were randomly divided into normal group 1 and model group 1,with 16 mice in each group,and the change in intestinal microbiota after modeling was observed. The other 60 mice were randomly divided into normal group 2,model group 2,probiotics group,and compound liver prescription group,with 15 mice in each group. The mice in the compound liver prescription group were given compound liver prescription by gavage at a dose of 15. 6 mg/kg/d,and those in model group 2 and normal group 2 were given an equal volume of sterile water by gavage once a day. The dose of gavage was clinical equivalent dose. The course of treatment was 14 days for all groups. The influence of compound liver prescription on intestinal microbiota in PHC mice was observed. Results： There were significant increases in the numbers of Bifidobacterium,Lactobacillus,Escherichia coli,and enterococci in PHC mice after modeling（ P〈0. 05）. Compared with model group 2,the compound liver prescription group and the probiotics group had significant reductions in the numbers of intestinal microbiota（ P〈0. 05）. There were no significant differences in intestinal bacteria between the compound liver prescription group and normal group 2,and there were no significant differences in Lactobacillus,Escherichia coli,and enterococci between the probiotics group and normal group2. There were no significant differences in the numbers of Lactobacillus,Escherichia coli,and enterococci between the compound liver prescription group and the probiotics group（ P〈0. 05）. Conclusion： PHC mice have imbalance of intestinal microbiota,and compound liver prescription can effectively regulate the disorder in intestinal microbiota in PHC mice.